Journal of Global Health: Home Journal of Global Health
Watch: Survival: The Story of Global Health - FREE
JoGH Recommends:

Peer Review Conference



Creative Commons Licence
This work is licensed under a
Creative Commons Attribution
4.0 International License
.


Annie Lo, Dora Polšek, and Simrita Sidhu

Abstract

Background

To provide an estimate for the burden of neural tube defects (NTD) in low– and middle–income countries (LMIC) and explore potential public health policies that may be implemented. Although effective interventions are available to prevent NTD, there is still considerable childhood morbidity and mortality present in LMIC.

Methods

A search of Medline, EMBASE, Global Health Library and PubMed identified 37 relevant studies that provided estimates of the burden of NTD in LMIC. Information on burden of total NTD and specific NTD types was separated according to the denominator into two groups: (i) estimates based on the number of live births only; and (ii) live births, stillbirths and terminations. The data was then extracted and analysed.

Results

The search retrieved NTD burden from 18 countries in 6 WHO regions. The overall burden calculated using the median from studies based on livebirths was 1.67/1000 (IQR = 0.98–3.49) for total NTD burden, 1.13/1000 (IQR = 0.75–1.73) for spina bifida, 0.25/1000 (IQR = 0.08–1.07) for anencephaly and 0.15/1000 (IQR = 0.08–0.23) for encephalocele. Corresponding estimates based on all pregnancies resulting in live births, still births and terminations were 2.55/1000 (IQR = 1.56–3.91) for total NTD burden, 1.04/1000 (IQR = 0.67–2.48) for spina bifida, 1.03/1000 (IQR = 0.67–1.60) for anencephaly and 0.21 (IQR = 0.16–0.28) for encephalocele. This translates into about 190 000neonates who are born each year with NTD in LMIC.

Conclusion

Limited available data on NTD in LMIC indicates the need for additional research that would improve the estimated burden of NTD and recommend suitable aid policies through maternal education on folic acid supplementation or food fortification.


Every year, more than 300 000 children are born with neural tube defects (NTD) [1-6]. NTD are a group of congenital abnormalities that still cause hundreds of thousands of deaths in 0–4 years age group, while similar number of surviving children remain disabled for life [1-6]. One of the Millennium Development Goals initiated by the United Nations was dedicated to reducing global mortality rates of children in this age group. Since 1990, global child mortality has been declining largely due to the focus on communicable diseases, which included the expansion of immunisation programmes, promotion of breast–feeding and increased provision of mosquito bednets in many countries worldwide [2]. This reduction of mortality has led to the neglected causes of child mortality to be exposed, including that of congenital abnormalities [3-6].

NTD are one of the most common presenting birth defects, arising as a result of incomplete closure of the brain or spinal cord in the 3rd and/or 4th week of pregnancy [3]. NTD can be classified as open or closed, depending on whether neural tissues are exposed or covered by skin, respectively. Open NTD are more frequent and include spina bifida, anencephaly and encephalocele. Closed NTD, such as tethered cord syndrome, are less frequent in comparison [4].

The best known risk factor for foetal NTD is maternal folate deficiency, arising from low levels of vitamin B9 (folic acid) [7,8]. Maternal vitamin B12 deficiency has only recently been shown to independently contribute to risk of NTD [9,10]. Additional risk factors for NTD development include a positive family history, smoking and indoor air pollution from coal and biomass heating used predominantly in developing countries [11-15]. Moreover, NTD are related to maternal socio–economic status, education, area of residence, and maternal nutrient deficiency or obesity [16,17].

NTD can be identified through simple prenatal testing using ultrasound imaging or maternal serum alpha–fetoprotein (MSAFP) level screening [18]. Abnormal elevation of MSAFP is a relatively specific and sensitive test for detection of NTD [18]. The abnormal presence of acetylcholinesterases (AChE) in amniotic fluid determined through amniocentesis can also be used for screening of NTD. However, a higher–than–normal test result is often not diagnostic and further evaluation should always be undertaken [19,20].

Since the discovery of folic acid as an effective intervention for prevention of neural tube defects [21], many countries have recommended folic acid intake before conception and during pregnancy. However, the dramatic 20% decrease in NTD birth burden after mandatory folic acid fortification (FAF) of enriched products in the US in 1998 showed that there may be more practical ways to administer this intervention [22]. Since this example, many countries such as Chile, Saudi Arabia and South Africa have implemented similar measures to staple food [23-25]. Despite folic acid being a well–known, cost–effective intervention, many developing countries continue to have either ineffective or no policy to increase maternal uptake of folic acid to prevent NTD.

The aims and objectives of this systematic review were:

1. To provide an estimate of NTD burden in LMIC by systematically reviewing literature available in public domain;

2. To examine and discuss the significance of these findings and consider clinical and cost–effective interventions and health policies with regards to NTD.

METHODS

A systematic literature review was conducted to search for published literature regarding population–based NTD burden estimates in LMIC, through the use of electronic databases: Medline, Embase, Global Health Library and PubMed. Potential further data were searched for on Google Scholar and by crosschecking reference lists from review articles. The search used Medical Subject Headings (MeSH) and key words for the burden of NTD in LMIC, as outlined by the World Bank. Limits of "human" and "2000–current" were used to obtain the most up to date NTD burden information. The last searches of the four databases were conducted on 6 February 2013. Search terms for Medline are shown in Table 1 and were modified for other databases as required.

Table 1.  Search terms for Medline
1. exp Developing Countries/
2. Developing countr*.tw
3. (developing adj3 countr*).tw
4. africa/ or africa, northern/ or algeria/ or egypt/ or libya/ or morocco/ or tunisia/ or "africa south of the sahara"/ or africa, central/ or cameroon/ or central african republic/ or chad/ or congo/ or "democratic republic of the congo"/ or equatorial guinea/ or gabon/ or africa, eastern/ or burundi/ or djibouti/ or eritrea/ or ethiopia/ or kenya/ or rwanda/ or somalia/ or sudan/ or tanzania/ or uganda/ or africa, southern/ or angola/ or botswana/ or lesotho/ or malawi/ or mozambique/ or namibia/ or south africa/ or swaziland/ or zambia/ or zimbabwe/ or benin/ or burkinafaso/ or cape verde/ or cote d'ivoire/ or gambia/ or ghana/ or guinea/ or guinea–bissau/ or liberia/ or mali/ or mauritania/ or niger/ or nigeria/ or senegal/ or sierra leone/ or togo/ or americas/ or caribbean region/ or west indies/ or "antigua and barbuda"/ or bahamas/ or barbados/ or cuba/ or dominica/ or dominican republic/ or grenada/ or guadeloupe/ or haiti/ or jamaica/ or martinique/ or netherlandsantilles/ or puertorico/ or "saint kitts and nevis"/ or saint lucia/ or "saint vincent and the grenadines"/ or "trinidad and tobago"/ or central america/ or belize/ or costa rica/ or el salvador/ or guatemala/ or honduras/ or nicaragua/ or panama/ or panama canal zone/ or latinamerica/ or mexico/ or south america/ or argentina/ or bolivia/ or brazil/ or chile/ or colombia/ or ecuador/ or frenchguiana/ or guyana/ or paraguay/ or peru/ or suriname/ or uruguay/ or venezuela/ or kazakhstan/ or kyrgyzstan/ or tajikistan/ or turkmenistan/ or uzbekistan/ or borneo/ or brunei/ or cambodia/ or east timor/ or indonesia/ or laos/ or malaysia/ or mekong valley/ or myanmar/ or philippines/ or thailand/ or vietnam/ or bangladesh/ or bhutan/ or india/ or sikkim/ or middle east/ or afghanistan/ or iran/ or iraq/ or israel/ or jordan/ or lebanon/ or saudiarabia/ or syria/ or turkey/ or united arab emirates/ or yemen/ or nepal/ or pakistan/ or srilanka/ or far east/ or china/ or tibet/ or "democratic people's republic of korea"/ or mongolia/ or taiwan/ or albania/ or lithuania/ or bosnia–herzegovina/ or bulgaria/ or "macedonia (republic)"/ or moldova/ or montenegro/ or romania/ or russia/ or bashkiria/ or dagestan/ or moscow/ or siberia/ or serbia/ or ukraine/ or armenia/ or atlantic islands/ or azores/ azerbaijan/ or "georgia (republic)"/ or comoros/ or madagascar/ or mauritius/ or seychelles/ or vanuatu/ or micronesia/ or palau/ or expsamoa/ or americansamoa/ or "independent state of samoa"/ or tonga/
5. exp neural tube defects/ or anencephaly/ or arnold–chiari malformation/ or encephalocele/ or meningocele/ or meningomyelocele/ or "pentalogy of cantrell"/ or exp spinal dysraphism/ or nervous system malformation
6. "neural tube defect".tw
7. "neural tube defects".tw
8. NTD.tw
9. exp Prevalence/
10. prevalen*.tw
11. 1 or 2 or 3 or 4
12. 5 or 6 or 7 or 8
13. 9 or 10
14. 11 and 12 and 13
15. Limit 14 to (humans and yr = "2000 –Current")


Study selection

The inclusion criteria for relevant papers included population or hospital based studies conducted in LMIC, which were geographically defined taking into account both the World Health Organization's and the World Bank's classification and treating any discrepancies in an inclusive, rather than exclusive way. The studies needed to have clearly expressed NTD burden showing a denominator, published between 2000 and 2013. The searches were limited to the period after the year 2000 in order to generate an estimate that is reflective of reasonably recent NTD trends. No limit on language and publication type was set. Keeping in mind that many babies with NTD are stillborn or terminated through miscarriages and abortions, we decided to include studies with live births, stillbirths and terminations as a separate body of evidence, in addition to studies that used live births–based denominators to report the burden of NTD.

Studies conducted solely in specialist hospital units were excluded, as they are likely to report a burden enriched for severe cases that would not be representative of the general population. Studies with incomplete data or where NTD burden could not be calculated were also excluded.

Data extraction

For the 37 retained studies, relevant data were extracted and compiled into Microsoft Excel spreadsheets. Data including authors, country, study size and diagnostic criteria for specific NTD type and total NTD cases were extracted. Types of NTD included spina bifida, myelomeningocele, meningocele, anencephaly, encephalocele and "other NTD types". Burden was expressed using the number of cases observed and a total sample of live births (or, alternatively, a total sample of live births, stillbirths and terminations).

Data analysis

When the number of affected children was not specifically provided in the study, it was calculated with the sample population using the following equation:

Estimated NTD burden = Number of observed NTD cases/Sample size (eg, number of live births) × 1000

The estimates of the burden provided in the retained studies were separated into two categories: those in which the denominator was based on the number of live births, and the other group in which live births, stillbirths and terminations were all included. Wherever this information was available for both categories, figures were separately added to the respective groups. The median estimate of the NTD burden and the inter–quartile range (IQR) for all LMIC regions was then determined, based on the retained 37 studies. Eventually, the median was multiplied by the number of livebirths in LMIC in the year 2010, according to UN Population Division's estimates (www.un.org/esa/population/‎), to determine the absolute number of NTD cases that has been introduced to the LMIC in 2010.

RESULTS

A review of relevant databases performed independently by two researchers (AL and SS) identified a total of 3339 studies, but only 37 satisfied all criteria for inclusion (as shown in Figure 1 ). Of the retained studies, 20 reported NTD rates in live births only, 14 reported rates in live births, stillbirths and terminations combined, and 3 studies reported both.

Figure 1.  A summary of the process of literature search.
jogh-04-010402-F1


The median sample size from all reviewed papers was 36 331, which corresponded well to a typical study size. The median sample population in studies based on live births was 35 974, compared to 49 534 in studies based on live births, stillbirths and terminations.

The search retrieved NTD burden from 18 countries in 6 WHO regions ( Table 2 ). The overall burden calculated using the median from studies based on live births was 1.67/1000 (IQR = 0.98–3.49) for total NTD burden ( Table 3 and 4 ), 1.13/1000 (IQR = 0.75–1.73) for spina bifida ( Table 3 and 5 ), 0.25/1000 (IQR = 0.08–1.07) for anencephaly ( Table 3 and 6 ) and 0.15/1000 (IQR = 0.08–0.23) for encephalocele ( Table 3 and 7 ).Corresponding estimates based on all pregnancies resulting in live births, still births and terminations were 2.55/1000 (IQR = 1.56–3.91) for total NTD burden ( Table 3 and 8 ), 1.04/1000 (IQR = 0.67–2.48) for spina bifida ( Table 3 and 9 ), 1.03/1000 (IQR = 0.67–1.60) for anencephaly ( Table 3 and 10 ) and 0.21 (IQR = 0.16–0.28) for encephalocele ( Table 3 and 11 ). This translates into about 190 000 neonates who are born each year with NTD in LMICs.

Table 2.  Distribution of retained studies by WHO regions
Number of studies
WHO region Country Total studies Live births only Live births, stillbirths & terminations
Western Pacific China 6 1 5
Malaysia 1 0 1
South East Asia India 3 2 1
Pakistan 1 1 0
Thailand 1 1 0
Eastern Mediterranean Jordan 2 2 0
Saudi Arabia 2 2 0
Iran 4 1 3
Europe Azerbaijan 1 0 1
Russia 1 1 0
Ukraine 1 0 1
Turkey 3 2 1
Africa Cameroon 1 1 0
South Africa 1 1 0
Americas Brazil 3 2 1
Colombia 1 1 0
Peru 1 1 0
Chile 4 1 3


Table 3.  A summary of estimates of the burden of neural tube defects and its sub–types from 37 retained studies from low and middle–income countries
Studied outcome Denominator Number of Studies Median (per 1000) Inter–quartile range (per 1000) Minimum(per 1000) Maximum (per 1000)
All neural tube defects LB 23 1.67 0.98–3.49 0.50 12.41
LB+SB+TP 17 2.55 1.56–3.91 0.86 19.94
Spina bifida LB 14 1.13 0.75–1.73 0.38 5.90
LB+SB+TP 15 1.04 0.67–2.48 0.35 5.81
Anencephaly LB 13 0.25 0.08–1.07 0.01 11.33
LB+SB+TP 16 1.03 0.67–1.60 0.30 8.26
Encephalocele LB 9 0.15 0.08–0.23 0.03 0.39
LB+SB+TP 13 0.21 0.16–0.28 0.07 2.65

LB – live births; LB+SB+TP – live births, stillbirths and terminated pregnancies



Table 4.  Studies that reported rates for total NTD burden based on live births only
Author and reference Sample size Cases Rate (per 1000 live births)
Amarin et al. [26] 61 447 16 0.95
Aqrabawi [11] 5088 33 6.50
Asindi et al. [27] 82 176 64 0.78
Bademci et al. [28] 5499 17 3.09
Behrooz et al. [29] 13 262 56 4.22
Chen et al. [30] 26 599 48 1.80
Cherian et al. [31] 1218 10 8.21
Cortes et al. [32] 59 627 67 1.12
Costa et al. [33] 9386 11 1.17
Gu et al. [13] 6420 25 3.89
Hertrampf et al. [34] 117 740 114 0.97
Kaur et al. [35] 7400 5 0.68
Khattak et al. [36] 5560 69 12.41
Mandiracioglu et al. [37] 36 331 56 1.54
Njamnshi et al. [38] 52 710 98 1.86
Pachajoa et al. [39] 32 995 55 1.67
Petrova et al. [40] 141 159 298 2.11
Pacheco et al. [41] 24 964 124 4.97
Ricks et al. [42] 35 974 72 2.00
Safdar et al. [24] 33 489 42 1.25
Sayed et al. [25] 46 021 45 0.98
Wasant et al. [43] 180 000 114 0.63
Yuskiv et al. [33] 75 609 38 0.50


Table5.  Studies that reported rates for the burden of spina bifida based on live births only
Author and reference Sample size Cases Rate(per 1000 live births)
Aqrabawi[11] 5088 30 5.90
Asindi et al. [27] 82 176 46 0.56
Bademci et al. [28] 5499 11 2.00
Behrooz et al. [29] 13 262 23 1.73
Cherian et al. [31] 1218 6 4.93
Costa et al. [44] 9386 7 0.75
Khattak et al. [36] 5560 5 0.90
Mandiracioglu et al. [37] 36 331 43 1.18
Njamnshi et al. [38] 52 710 65 1.23
Petrova et al. [40] 141 159 147 1.04
Ricks et al. [42] 35 974 62 1.72
Safdar et al. [24] 33 489 36 1.07
Sayed et al. [25] 46 021 25 0.54
Yuskiv et al. [33] 75 609 29 0.38


Table 6.  Studies that reported rates for the burden of anencephaly based on live births only
Author and reference Sample size Cases Rate (per 1000 live births)
Asindi et al. [27] 82 176 3 0.04
Behrooz et al. [29] 13 262 30 2.26
Cherian et al. [31] 1218 3 2.46
Costa et al. [44] 9386 1 0.11
Khattak et al. [36] 5560 63 11.33
Mandiracioglu et al. [45] 36 331 4 0.11
Njamnshi et al. [38] 52 710 4 0.08
Petrova et al. [40] 141 159 151 1.07
Ricks et al. [42] 35 974 10 0.28
Safdar et al. [24] 33 489 1 0.03
Sayed et al. [25] 46 021 17 0.37
Wasant et al. [43] 180 000 45 0.25
Yuskiv et al. [33] 75 609 1 0.01


Table 7.  Studies that reported rates for the burden of encepalocele based on live births only
Author and reference Sample size Cases Rate (per 1000 live births)
Aqrabawi [11] 5088 2 0.39
Asindi et al. [27] 82 176 15 0.18
Behrooz et al. [29] 13 262 3 0.23
Costa et al. [44] 9386 3 0.32
Mandiracioglu et al. [45] 36 331 1 0.03
Njamnshi et al. [38] 52 710 5 0.09
Safdar et al. [24] 33 489 5 0.15
Wasant et al. [43] 180 000 14 0.08
Yuskiv et al. [33] 75 609 3 0.03


Table 8.  Studies that reported rates for total NTD burden based on live births, stillbirths and terminations of pregnancy
Author and reference Sample size Cases Rate (per 1000 live births stillbirths and terminations)
Aguiar et al. [46] 18 807 89 4.73
Cortes et al. [32] 60 072 94 1.56
Cortes et al. [12] 486 779 419 0.86
Dai et al. [46] 2 281 616 2873 1.30
Golalipour et al. [47] 37 951 109 2.87
Golalipour et al. [12] 30 639 78 2.55
Golalipour et al. [48] 49 534 194 3.91
Gu et al. [13] 6420 128 19.94
Li et al. [10] 11 534 159 13.79
Liu et al. [49] 99 888 122 1.22
Mahadevan et al. [45] 54 738 310 5.66
Nazer et al. [50] 434 624 740 1.70
Noraihan et al. [51] 34 109 37 1.08
Onrat et al. [52] 8631 31 3.59
Rad et al. [53] 14 121 117 2.57
Yuskiv et al. [33] 75 928 159 2.09
Zhang et al. [54] 62 373 126 2.02


Table 9.  Studies that reported rates for the burden of spina bifida based on live births, stillbirths and terminations of pregnancy
Author and reference Sample size Cases Rate (per 1000 live births, stillbirths and terminations)
Cortes et al. [32] 60 072 46 0.77
Cortes et al. [12] 486 779 204 0.42
Golalipour et al. [47] 37 951 62 1.63
Golalipour et al. [12] 30 639 39 1.27
Gu et al. [13] 6420 25 3.89
Li et al. [10] 11 534 67 5.81
Liu et al. [49] 99 888 59 0.59
Mahadevan et al. [45] 54 738 170 3.11
Noraihan et al. [51] 34 109 12 0.35
Onrat et al. [52] 8631 9 1.04
Yuskiv et al. [33] 75 928 64 0.84
Aguiar et al. [55] 18 807 47 2.49
Dai et al. [46] 2 281 616 1369 0.60
Nazer et al. [50] 434 624 374 0.86
Rad et al. [53] 14 121 35 2.48


Table 10.  Studies that reported rates for the burden of anencephaly based on live births, stillbirths and terminations of pregnancy
Author and reference Sample size Cases Rate (per 1000 live births, stillbirths and terminations)
Aguiar et al. [55] 18 807 24 1.28
Cortes et al. [32] 60 072 37 0.62
Cortes et al. [12] 486 779 147 0.30
Dai et al. [46] 2 281 616 1140 0.50
Golalipour et al. [47] 37 951 43 1.40
Golalipour et al. [12] 30 639 35 0.92
Golalipour et al. [48] 49 534 56 1.13
Gu et al. [13] 6420 53 8.26
Li et al. [10] 11 534 75 6.50
Liu et al. [49] 99 888 42 0.42
Mahadevan et al. [45] 54 738 98 1.80
Nazer et al. [50] 434 624 311 0.72
Noraihan et al. [51] 34 109 25 0.73
Onrat et al. [52] 8631 12 1.39
Rad et al. [53] 14 121 78 5.52
Yuskiv et al. [33] 75 928 62 0.82


Table 11.  Studies that reported rates for the burden of encephalocele based on live births, stillbirths and terminations of pregnancy
Author and reference Sample size Cases Rate (per 1000 live births stillbirths and terminations)
Aguiar et al. [55] 18 807 5 0.27
Cortes et al. [32] 60 072 11 0.18
Dai et al. [46] 2 281 616 365 0.16
Golalipour et al. [47] 37 951 4 0.11
Golalipour et al. [12] 30 639 4 0.13
Gu et al. [13] 6420 17 2.65
Li et al. [10] 11 534 17 1.47
Liu et al. [49] 99 888 7 0.07
Mahadevan et al. [45] 54 738 36 0.66
Nazer et al. [50] 434 624 91 0.21
Onrat et al. [52] 8631 2 0.23
Rad et al. [53] 14 121 4 0.28
Yuskiv et al. [33] 75 928 12 0.16


As expected, when comparing IQRs as the robust predictions, overall NTD burden estimates were found to be higher in the live births, stillbirths and terminations group in comparison to studies that included only live births, while spina bifida was the most commonly reported NTD type. Moreover, there is internal consistency in the presented estimates, because the sum of the specific NTD types always fits into the "envelope" of all NTD.

DISCUSSION

This systematic literature review aimed to examine the burden of NTD in LMIC. It is, to our knowledge, the first study to quantitatively estimate the total NTD burden in LMIC. As such, the burden estimates can be successfully used in the much–needed preventive policy development in LMIC with high risk of NTD.

The results from the 37 selected studies [10-13,23-55] suggest that NTD burden is approximately twice as high, if not higher, in LMIC than in high–income countries [56-58]. The findings from live birth–only studies showed that the median total NTD burden is 1.67 per 1000 live births, although there were reports of significantly higher values, with a maximum burden as high as 12.41/1000. The overall median is greater in studies where live births, stillbirths and terminations were taken into account, where the burden is 2.55 per 1000 and maximum reported burden of 19.94/1000. This is expected, as a considerable proportion of NTD result in stillbirths and terminations [59,60].

Significant discrepancies between reported burdens from the same country were sometimes observed. These differences were attributed to different study settings, for example in rural and urban India [31,35,45], or different time periods as seen in two studies from Jordan [11,26]. Extremely high burden of NTD of 13.79 and 19.94 was observed in two studies from China, although the samples were rather small, indicating a possible selection bias [10,13].

Regardless of the progress in control of NTDs observed in high–income countries, NTD continue to be a problem of significant public health impact in LMIC. NTD have detrimental physical and emotional effects on the affected children and their caregivers, and may present a life–long important and often insurmountable economic problem, especially to poor families [52]. The cost of raising a child with spina bifida from birth to 18 years of age in Chile was estimated to be around US$ 120 000 [34]. These expenses, apart from causing individual deprivation, are a significant economic burden on the level of the whole society, causing a vicious circle of poverty in the LMIC.

Hundreds of thousands of live born babies are affected by NTD in LMIC, which remain an important and preventable cause of morbidity and mortality. Thus, effective policies for prevention are vital to reduce the burden of NTD on individuals and on society. Up to now, more than 59 countries have committed to mandatory fortification programmes [59,61,62]. However, many LMIC still have ineffective recommendations and policies towards folic acid uptake. Some countries have recommended the improvement of daily diet and folic acid supplement use, but do not have a mandatory policy [59,61,62]. Recommendation provides a good starting point for reducing NTD burden in LMIC. However, many households in LMIC may not be able to afford folic acid supplementation throughout pregnancy [63]. As shown by the example from the US where NTD burden had fallen by 20% after mandatory fortification, recommendation alone, even without the economic constraint, is not likely to provide a feasible and effective solution [22].Interestingly, survey conducted in the UK found that there was only a marginal increase in folic acid intake in women who were planning pregnancy [64]. Additionally, around half of all pregnancies in the US are unexpected [58,62], and this figure may be even higher in LMIC where there may be limited availability of contraception.

Despite obvious benefits, before promoting folic acid fortification, many factors must be considered. Currently no country in the European Union has compulsory fortification schemes due to risk consideration and campaigns against 'mass medication' [65,66]. Safety, ethics and economic feasibility of a FAF programme must be taken into account before implementing such a policy, especially on a whole–country level. Nevertheless, current high burden of NTD in LMIC stresses the need for a comprehensive prevention program.

For consistent and reliable estimates on burden of NTD, it is important to set up vital and birth registration documentation programs in countries that lack coherent information on NTD burden. Not only will this aid in the prevention and treatment of NTD, but it will also enable policy makers to monitor the benefits of implemented prevention programs. This may be particularly important for countries in the African WHO region, where a high NTD burden is expected, but from which only a few studies have been published [67,68].

The reported NTD burden was estimated based on a limited number of available studies, some with very variable sample sizes that differed in inclusion of stillbirths and terminated births in the study design. We could not use meta–analysis, because studies came from such heterogeneous contexts that we didn't feel it was justified to present anything beyond simple median and IQR in this initial estimate. This is partly because not all studies adhered to ICD–10 classification of NTD and were not uniformly conducted regarding method of diagnosis and reporting of NTD type, enabling potential over– or under–estimation of NTD burden through misdiagnosis. Also, the technical restrictions of accounting for all stillbirths and terminations in the examined studies limited the precision of our estimated burden in that population [68].

Finally, the data was available from studies conducted in only 18 countries, implying that the studied sample is unlikely to be representative of all the LMIC globally. Regardless of these significant limitations, it is our opinion that the estimated burdens reported in the results provide useful data for initial assessment of NTD burden in LMIC. An increase in high quality research on NTD, especially with regards to gender and geographical regions, should be prioritised to allow more accurate NTD estimates. This would make the burden of the problem easier to estimate in a more credible way, and allow effective planning of prevention and intervention to minimise the risks for NTD.

Acknowledgements

Funding: There was no formal sponsorship of this research.

Ethical approval: None required.

Authorship declaration: AL performed the initial systematic review and literature search and wrote the first draft of the manuscript. DP has revised the first draft and performed calculations. SS has performed a parallel review, double–checked all calculations, revised the second draft and prepared the final version of the paper.

Competing interest: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author). They declared no competing interests.

References

[1] Shibuya K, Murray CJ. Congenital anomalies. In: Murray CJ, Lopez AD (eds). Health dimensions of sex and reproduction: the global burden of sexually transmitted diseases, HIV, maternal conditions, perinatal disorders, and congenital anomalies. Boston, Massachusetts, USA: Harvard School of Public Health, on behalf of the World Health Organization and the World Bank;1998. pp. 455–512.

[2] United Nations. The Millennium Development Goals Report. 2012. Available at: http://mdgs.un.org/unsd/mdg/Resources/Static/Products/Progress2012/English2012.pdf#page=28. Accessed 20th April 2013.

[3] Duke Centre for Human Genetics. Neural Tube Defects (NTDs). 2012. Available at: http://www.chg.duke.edu/diseases/ntd.html. Accessed 20th April 2013.

[4] LD Botto CA Moore MJ Khoury JD Erickson Neural tube defects.N Engl J Med1999341150919DOI: 10.1056/NEJM199911113412006. [PMID:10559453]

[5] Spina Bifida Association. Spina Bifida Occulta. 2012. Available at: http://www.spinabifidaassociation.org/site/c.evKRI7OXIoJ8H/b.8277205/. Accessed 20th April 2013.

[6] Christianson A, Howson CP, Modell B. Global Report on Birth Defects: The Hidden Toll of Dying and Disabled children. March of Dimes. 2006. Available at: http://www.marchofdimes.com/mission/globalprograms_birthdefectsreport.html. Accessed 20th April 2013.

[7] PN Kirke AM Molloy LE Daly H Burke DG Weir JM Scott Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects.Q J Med1993867038[PMID:8265769]

[8] NK Bjorklund R Gordan A hypothesis linking low folate intake to neural tube defects due to failure of post–translation methylations of the cytoskeletion.Int J Dev Biol20065013541DOI: 10.1387/ijdb.052102nb. [PMID:16479482]

[9] ZP Wang XX Shang ZT Zhao Low maternal vitamin B12 is a risk factor for neural tube defects: a meta–analysis.J Matern Fetal Neonatal Med20122538994DOI: 10.3109/14767058.2011.580800. [PMID:21627554]

[10] Z Li A Ren L Zhang R Ye S Li J Zheng Extremely high prevalence of NTD in a 4–county area of Shanxi Province, China.Birth Defects Res A Clin Mol Teratol20067623740DOI: 10.1002/bdra.20248. [PMID:16575897]

[11] HE Aqrabawi Incidence of neural tube defects among neonates at King Hussein Medical Centre, Jordan.East Mediterr Health J20051181923[PMID:16700398]

[12] M Golalipour L Najafi A Keshtkar Neural tube defects in native Fars ethnicity in Northern Iran.Iran J Public Health20103911623[PMID:23113030]

[13] X Gu L Lin X Zheng T Zhang X Song J Wang High prevalence of NTDs in Shanxi Province: a combined epidemiological approach.Birth Defects Res A Clin Mol Teratol2007797027DOI: 10.1002/bdra.20397. [PMID:17729293]

[14] L Suarez M Felkner JD Brender M Canfield K Hendricks Maternal exposures to cigarette smoke, alcohol and street drugs and neural tube defect occurrence in offspring.Matern Child Health J200812394401DOI: 10.1007/s10995-007-0251-y. [PMID:17641961]

[15] Z Li L Zhang R Ye L Pei J Liu X Zheng Indoor air pollution from coal combustion and the risk of neural tube defects in a rural population in Shanxi Province, China.Am J Epidemiol20111744518DOI: 10.1093/aje/kwr108. [PMID:21659350]

[16] E TunÇbilek K Boduroglu M Alikasifoglu Neural tube defects in Turkey: prevalence, distribution and risk factor.Turk J Pediatr199941299305[PMID:10770089]

[17] ML Watkins SA Rasmussen MA Honein LD Botto CA Moore Maternal obesity and risk for birth defects.Pediatrics200311111528[PMID:12728129]

[18] Mayo Medical Laboratories. Test ID: MAFP. 2013. Available at: http://www.mayomedicallaboratories.com/test–catalog/Clinical+and+Interpretive/81169. Accessed 21 April 2013.

[19] Mayo Medical Laboratories. Test ID: ACHE. 2013. Available at: http://www.mayomedicallaboratories.com/test–catalog/Clinical+and+Interpretive/9287. Accessed 21 April 2013.

[20] National Cancer Institute. Computed Tomography (CT): A guide for Health Care. 2012. Available at: http://www.cancer.gov/cancertopics/causes/radiation/radiation–risks–pediatric–CT. Accessed 21st April 2013.

[21] Prevention of neural tube defects: results of the Medical Research Council Vitamin Study.Lancet19913381317DOI: 10.1016/0140-6736(91)90133-A. [PMID:1677062]

[22] MA Honein LJ Paulozzi TJ Mathews JD Erickson LY Wong Impact of folic acid fortification of the US food supply on the occurrence of neural tube defect.JAMA200128529816DOI: 10.1001/jama.285.23.2981. [PMID:11410096]

[23] F Cort´s C Mellado RA Pardo LA Villarroel E Hertrampf Wheat flour fortification with folic acid: changes in neural tube defect rates in Chile.Am J Med Genet A2012158A188590DOI: 10.1002/ajmg.a.35430. [PMID:22711368]

[24] OY Safdar AA Al–Dabbagh WA Abuelieneen JA Kari Decline in the incidence of neural tube defects after the national fortification of flour (1997–2005).Saudi Med J20072812279[PMID:17676207]

[25] AR Sayed D Bourne R Pattinson J Nixon B Henderson Decline in the prevalence of neural tube defects following folic acid fortification and its cost–benefit in South Africa.Birth Defects Res A Clin Mol Teratol2008822116DOI: 10.1002/bdra.20442. [PMID:18338391]

[26] ZO Amarin AZ Obeidat Effect of folic acid fortification on the incidence of neural tube defects.Paediatr Perinat Epidemiol20102434951DOI: 10.1111/j.1365-3016.2010.01123.x. [PMID:20618724]

[27] A Asindi A Al–Shehri Neural tube defects in the Asir Region of Saudi Arabia.Ann Saudi Med200121269[PMID:17264584]

[28] G Bademci M Saygun F Batay A Cakmak H Basar H Anbarci Prevalence of primary tethered cord syndrome associated with occult spinal dysraphism in primary school children in Turkey.Pediatr Neurosurg200642413DOI: 10.1159/000089503. [PMID:16357495]

[29] A Behrooz MH Gorjizadeh Prevalence and correlates of neural tube defects in South West Iran: Retrospective analysis.Sultan Qaboos Univ Med J20077314[PMID:21654942]

[30] Chen G, Song Z, Ji Y, Zhang L, Pei L, Chen J, et al. Prevention of NTDs with periconeptional multivitamin supplementation containing folic acid in China. Birth Defect Res A Clin Mol Teratol. 2008;82:592–6.

[31] A Cherian S Seena RK Bullock AC Antony Incidence of neural tube defects in the least–developed area of India: a population–based study.Lancet20053669301DOI: 10.1016/S0140-6736(05)67319-9. [PMID:16154020]

[32] F Cort´s C Mellado E Hertrampf A Alliende S Castillo Frequency of neural tube defects in public maternity during 1999 in Santiago, Chile.Rev Med Chil200112927784[PMID:11372295]

[33] N Yuskiv CO Andelin S Polischuk O Shevchuk Z Sosynyuk T Vihovska High rates of neural tube defects in Ukraine.Birth Defects Res A Clin Mol Teratol2004704002DOI: 10.1002/bdra.20020. [PMID:15211709]

[34] E Hertrampf F Cort´s National food fortification program with folic acid in Chile.Food Nutr Bull2008292SupplS2317[PMID:18709898]

[35] G Kaur J Srivastav A Kaur A Huria P Goel R Kaur Maternal serum second trimester screening for the chromosomal disorders and neural tube defects in a government hospital of North India.Prenat Diagn20123211926DOI: 10.1002/pd.3984. [PMID:23055346]

[36] ST Khattak M Khan T Naheed IU Khattak M Ismali Prevalence and management of anencephaly at Saidu Teaching Hospital.J Ayub Med Coll Abbottabad201022613[PMID:22455263]

[37] A Mandiracioğlu I Ulman E Lüleci C Ulman The incidence and risk factors of neural tube defects in Izmir, Turkey: a nested case–control study.Turk J Pediatr20044621420[PMID:15503473]

[38] AK Njamnshi Vde P Djientcheu A Lekoubou M Guemse MT Obama R Mbu Neural tube defects are rare among black Americans but not in sub–Saharan black Africans: the case of Yaounde – Cameroon.J Neurol Sci2008270137DOI: 10.1016/j.jns.2008.01.010. [PMID:18295800]

[39] H Pachajoa Y Ariza C Isaza F M´ndez Major birth defects in a third–level hospital in Cali, Colombia 2004–2008.Rev Salud Publica (Bogota)20111315262[PMID:22030798]

[40] JG Petrova A Vatskjold The incidence of neural tube defects in Norway and the Arkhangelskaja Oblast in Russia and the association with maternal age.Acta Obstet Gynecol Scand20098866772DOI: 10.1080/00016340902898008. [PMID:19353336]

[41] SS Pacheco C Braga AI Souza JN Figueiroa Neural tube defects prevalence in newborn infants in the Women Care Center of the Instituto Materno Infantil Prof. Fernando Figueira.Rev Bras Saude Mater Infant20066Suppl 1S3542

[42] DJ Ricks CA Rees KA Osborn BT Crookston K Leaver SB Merrill Peru's national folic acid fortification program and its effect on neural tube defects in Lima.Rev Panam Salud Publica2012323918DOI: 10.1590/S1020-49892012001400001. [PMID:23370181]

[43] P Wasant A Sathienkijkanchai Neural tube defects at Sirirajhospital, Bangkok, Thailand – 10 years review (1990–1999).J Med Assoc Thai200588Suppl 8S929[PMID:16858850]

[44] CM Costa SG da Gama C Leal Mdo Congenital malformations in Rio de Janeiro, Brazil: prevalence and associated factors.Cad Saude Publica200622242331DOI: 10.1590/S0102-311X2006001100016. [PMID:17091179]

[45] B Mahadevan BV Bhat Neural tube defects in Pondicherry.Indian J Pediatr2005725579DOI: 10.1007/BF02724177. [PMID:16077237]

[46] L Dai J Zhu G Zhou Y Wang Y Wu L Miao Dynamic monitoring of neural tube defects in China during 1996 to 2000.Zhonghua Yu Fang Yi Xue Za Zhi2002364025[PMID:12641978]

[47] MJ Golalipour E Mobasheri MA Vakilil AA Keshtkar Epidemiology of neural tube defects in north Iran, 1998 – 2003.East Mediterr Health J2007135606[PMID:17687828]

[48] MJ Golalipour L Najafi AA Keshtkar Prevalence of anencephaly in Gorgan, Northern Iran.Arch Iran Med201013347[PMID:20039767]

[49] J Liu GZ Yang JL Zhou SP Cao DH Chau HF Kung Prevalence of neural tube defects in economically and socially deprived area of China.Childs Nerv Syst200723111924DOI: 10.1007/s00381-007-0344-3. [PMID:17450368]

[50] H J Nazer Congenital malformations in Latin America in the period 1995–2008.Rev Med Chil2011139728[PMID:21526320]

[51] MN Noraihan MH See R Raja TP Baskaran EM Symonds Audit of birth defects in 34,109 deliveries in a tertiary referral center.Med J Malaysia2005604608[PMID:16570708]

[52] ST Onrat H Seyman M Honuk Incidence of neural tube defects in Afyonkarahisar, Western Turkey.Genet Mol Res2009815461DOI: 10.4238/vol8-1gmr552. [PMID:19283682]

[53] IA Rad HR Farrokh–Islamlou M Khoshkalam Neural tube defects prevalence in a hospital–based study in UrmiaIran J Child Neurol200821923

[54] KZ Xiao ZY Zhang YM Su FQ Liu ZZ Yan ZQ Jiang Central nervous system congenital malformations, especially neural tube defects in 29 provinces, metropolitan cities and autonomous regions of China: Chinese Birth Defects Monitoring Program.Int J Epidemiol19901997882DOI: 10.1093/ije/19.4.978. [PMID:2084031]

[55] MJ Aguiar AS Campos RA Aguiar AM Lana RL Magalhăes LT Babeto Neural tube defects and associated factors in liveborn and stillborn infants.J Pediatr (Rio J)20037912934DOI: 10.2223/JPED.964. [PMID:14502333]

[56] SC Tinker ME Cogswell O Devine RJ Berry Folic acid intake among U.S. women aged 15–44 years, National Health and Nutrition Examination Survey, 2003–2006.Am J Prev Med20103853442DOI: 10.1016/j.amepre.2010.01.025. [PMID:20347553]

[57] SD Grosse NJ Waitzman PS Romano J Mulinare Re–evaluation the benefits of folic acid fortification in the United States: economic analysis, regulation and public health.Am J Public Health200595191722DOI: 10.2105/AJPH.2004.058859. [PMID:16195513]

[58] IH Yen MJ Khoury JD Erickson LM James GD Waters RJ Berry The changing epidemiology of neural tube defects. United States, 1968–1989.Am J Dis Child199214685761DOI: 10.1001/archpedi.1992.02160190089028. [PMID:1496959]

[59] World Health Organization. Weekly iron–folic acid supplementation (WIFS) in Women of Reproductive age: Its role in promoting optimal maternal and child health. 2009. Available at: http://www.who.int/nutrition/publications/micronutrients/weekly_iron_folicacid.pdf. Accessed 21st April 2013.

[60] National Library of Medicine. Spina Bifida. 2013. Available at: http://www.nlm.nih.gov/medlineplus/spinabifida.html. Accessed 20th April 2013.

[61] RJ Berry L Bailey J Mulinare C Bower Folic Acid Working Group Fortification of flour with folic acid.Food Nutr Bull201031SupplS2235[PMID:20629350]

[62] KS Crider LB Bailey RJ Berry Folic acid fortification – its history, effect, concerns, and future directions.Nutrients2011337084DOI: 10.3390/nu3030370. [PMID:22254102]

[63] M Chopra H Campbell I Rudan Understanding the determinants of the complex interplay between cost–effectiveness and equitable impact in maternal and child mortality reduction.J Glob Health20122010406DOI: 10.7189/jogh.01.010406. [PMID:23198135]

[64] SR Crozier SM Robinson SE Borland KM Godfrey C Cooper H Inskip SWS study group Do women change their health behaviours in pregnancy? Findings from the Southampton Women's Survey.Paediatr Perinat Epidemiol20092344653DOI: 10.1111/j.1365-3016.2009.01036.x. [PMID:19689495]

[65] A Russell The UK campaign on folic acid and flour fortification.Cerebrospinal Fluid Res20063Suppl 1S33DOI: 10.1186/1743-8454-3-S1-S33

[66] FAO and WHO. Folate and folic acid. 2002. Available at: http://www.fao.org/docrep/004/Y2809E/y2809e0a.htm. Accessed 25th April 2013.

[67] A Campbell I Rudan Systematic review of birth cohort studies in Africa.J Glob Health201114658[PMID:23198102]

[68] L Frey WA Hauser Epidemiology of neural tube defects.Epilepsia200344Suppl 3413DOI: 10.1046/j.1528-1157.44.s3.2.x. [PMID:12790881]



Journal of Global Health (ISSN 2047-2986), Edinburgh University Global Health Society
Designed by